Median Price Set by Brand Name Drug Makers on New Treatments Climbs to $300,000 In case you missed it, on Friday, Reuters released a new analysis which found that the median annual price among new drugs approved by the U.S. Food and Drug Administration (FDA) in 2023 reached $300,000. This number was 35 percent higher than the
GLP-1 Weight-Loss Leaders “Blow Past” Wall Street Projections in Q4 2023, Hike Prices on at Least 20 Brand Name Products in First Weeks of 2024 Big Pharma giants Eli Lilly and Novo Nordisk…
More Big Pharma Giants Report Earnings That Top Wall Street Expectations While Continuing to Hike Prices on Dozens of Brand Name Drugs Merck, Bristol Myers Squibb…
Patent Abuse Designed to Extend Monopolies, Block Competition and Keep Prices High Takes Center Stage at HELP Committee Hearing On Thursday, the U.S. Senate Committee on Health, Education, Labor and…
Big Pharma Giants Continue Q4 Earnings Besting Wall Street Expectations Pfizer and GlaxoSmithKline (GSK) are the latest Big Pharma giants to report Wall Street-besting earnings for the fourth…
JAMA Analysis Finds Patents for Active Ingredients for Weight Loss Drugs Significantly Lower than for Other Prescription Drugs That Rely on Drug-Device Combinations A new analysis published in JAMA…
Lawmakers and Experts Will Discuss Solutions to Hold Big Pharma Accountable for Anti-Competitive Tactics That Keep Drug Prices High Washington, D.C. – On Tuesday, February 6 at 10:00 AM, Campaign…
Big Pharma Giant Kicks Off Q4 Earnings After Hiking Prices More Than 40 Times in 2023 This past week, brand name drug giant Johnson & Johnson kicked off the first round of Big Pharma earnings…
Big Pharma Price Hikes, Rising Launch Prices And Patent Abuse Impose Massive Costs on Patients, Taxpayers, and the U.S. Health Care System Tomorrow, the U.S.
Rx Price Watch Analysis Finds Big Pharma Price Increases Outpaced Inflation Every Year Except One Between 2006 and 2020 A new report from AARP finds Big Pharma “consistently” increased prices…